Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.
The presence of the c-erbB-2 protein, demonstrated immunohistochemically with antibody 21N, has been studied in 72 cases of pure mammary ductal carcinoma in situ. Sixty-one percent of cases showed positive staining. The protein was always present in large-cell comedo type of ductal carcinoma in situ, and never in small-cell cribriform/micropapillary type of ductal carcinoma in situ. When nuclear size was measured, staining was associated with tumors containing cells with large nuclei measuring up to 20 mu, and was never present in lesions containing cells with small nuclei measuring 10 mu or less. In tumors of mixed histopathologic type of ductal carcinoma in situ, variable staining was seen; the cells with small nuclei never stained, while the majority of cells with large nuclei reacted positively. The possible relevance of these findings to the biologic behavior of DCIS is discussed.
Bartkova
J
J
Imperial Cancer Research Fund Clinical Oncology Units, Guy's Hospital, London, England.
Barnes
D M
DM
Millis
R R
RR
Gullick
W J
WJ
D001943:Breast Neoplasms / Q000737:chemistry*; D002278:Carcinoma in Situ / Q000737:chemistry*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000737:chemistry*; D006801:Humans; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D018719:Erb-b2 Receptor Tyrosine Kinases
D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases